BioCentury
DATA GRAPHICS | Data Byte

2023’s biotech reverse mergers

Half of the U.S.-listed biotechs that announced reverse mergers this year had been public for four years or less

December 20, 2023 1:43 AM UTC

Of the 12 U.S.-listed biotech companies that announced reverse mergers this year, half had gone public in 2019 or later, with the shortest interval between IPO and reverse merger just under two years.

Three of the 12 companies — Graphite Bio Inc. (NASDAQ:GRPH), Talaris Therapeutics Inc. and
Angion Biomedica Corp. — were in the class of 2021 IPOs, the year the biotech markets peaked, before its slide into the bear market that has persisted since...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article